SOST and osteogenesis imperfecta: This OI preclinical model has been previously used to study the therapeutic effects of sclerostin antibody treatment,31 and combination therapy of sclerostin antibody and bisphosphonate.27 Baseline characterization of osteoblasts cultured from this mouse model confirmed that the mutation resulted in an unconventional ER stress response with downstream signalling consequences.